We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

274 hedge funds and large institutions have $3.85B invested in Intra-Cellular Therapies Inc. in 2022 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 103 increasing their positions, 86 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 35

20% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 86

13% more call options, than puts

Call options by funds: $21.3M | Put options by funds: $18.9M

3% more funds holding

Funds holding: 266 → 274 (+8)

16% less capital invested

Capital invested by funds: $4.57B → $3.85B (-$727M)

36% less funds holding in top 10

Funds holding in top 10: 11 → 7 (-4)

Holders
274
Holders Change
+8
Holders Change %
+3.01%
% of All Funds
4.72%
Holding in Top 10
7
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-36.36%
% of All Funds
0.12%
New
43
Increased
103
Reduced
86
Closed
35
Calls
$21.3M
Puts
$18.9M
Net Calls
+$2.43M
Net Calls Change
-$6.17M

Top Buyers

1
GKIM
GW&K Investment Management
Massachusetts
+$46.1M
2
Invesco
Invesco
Georgia
+$45.3M
3
Millennium Management
Millennium Management
New York
+$42M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$36.3M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$34.3M

Top Sellers

1
Victory Capital Management
Victory Capital Management
Texas
-$43.9M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$36.5M
3
DCM
Driehaus Capital Management
Illinois
-$29.4M
4
SCM
Suvretta Capital Management
New York
-$25.4M
5
CAM
Cormorant Asset Management
Massachusetts
-$15.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
101
Brookfield Corp
Ontario, Canada
$2.27M +$2.55M +48,762 New
MIM
102
MetLife Investment Management
New Jersey
$2.27M +$59.3K +1,135 +2%
Assenagon Asset Management
103
Assenagon Asset Management
Luxembourg
$2.21M +$430K +8,232 +21%
Truist Financial
104
Truist Financial
North Carolina
$2.19M +$2.46M +47,021 New
Principal Financial Group
105
Principal Financial Group
Iowa
$2.13M -$7.65M -146,465 -76%
CL
106
CSS LLC
Illinois
$2.11M -$758K -14,513 -24%
Mirae Asset Global Investments
107
Mirae Asset Global Investments
South Korea
$2.08M +$757K +14,482 +48%
Royal Bank of Canada
108
Royal Bank of Canada
Ontario, Canada
$2.04M +$1.3M +24,967 +132%
AIG
109
American International Group
New York
$2.02M +$32.1K +615 +1%
OCM
110
Osterweis Capital Management
California
$1.95M +$2.19M +41,895 New
DekaBank Deutsche Girozentrale
111
DekaBank Deutsche Girozentrale
Germany
$1.93M -$19K -364 -0.8%
FAM
112
Fred Alger Management
New York
$1.79M -$2.41M -46,184 -55%
MOACM
113
Mutual of America Capital Management
New York
$1.74M +$1.95M +37,362 New
EAM
114
EFG Asset Management
Oregon
$1.74M -$147K -2,811 -7%
Stifel Financial
115
Stifel Financial
Missouri
$1.68M +$157 +3 +0%
Manulife (Manufacturers Life Insurance)
116
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.68M -$31.9K -611 -2%
Walleye Trading
117
Walleye Trading
New York
$1.67M +$1.29M +24,695 +220%
CS
118
Candriam SCA
Luxembourg
$1.67M – – –
1CM
119
1492 Capital Management
Wisconsin
$1.63M +$569K +10,891 +45%
Susquehanna International Group
120
Susquehanna International Group
Pennsylvania
$1.61M +$1.55M +29,682 +611%
Wells Fargo
121
Wells Fargo
California
$1.51M -$30.7K -587 -2%
B
122
Bailard
California
$1.5M – – –
SSA
123
Schonfeld Strategic Advisors
New York
$1.49M -$1.63M -31,130 -49%
Prudential Financial
124
Prudential Financial
New Jersey
$1.48M -$13.3M -253,783 -89%
BGIM
125
Brandywine Global Investment Management
Pennsylvania
$1.47M – – –
3 4
5
6 7

ITCI Hedge Fund Activity: Q3 2022 in Review

274 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2022, worth a combined $3.85B — down 16% from $4.57B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new ITCI positions and 35 closed out — a net gain of 8 holders — while 103 added to existing stakes and 86 trimmed.

The largest buyer was GW&K Investment Management, adding an estimated $46.1M. The largest seller was Victory Capital Management, cutting an estimated $43.9M.

  • 274 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2022, up from 266 in Q2 2022.
  • Funds reported $3.85B of Intra-Cellular Therapies Inc. stock for Q3 2022, down 16% quarter-over-quarter.
  • 43 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2022 and 35 closed out, a net change of +8 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q3 2022 was GW&K Investment Management, an estimated $46.1M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q3 2022 was Victory Capital Management, an estimated $43.9M sold.

Based on aggregated 13F filings for Q3 2022.